"The US Food and Drug Administration (FDA) is ordering stricter warnings and contraindications for the anemia drug ferumoxytol (Ferumoxytol, AMAG Pharmaceuticals), stating that even with current warnings, there have been 79 anaphylactic r"...
The following adverse reactions are discussed in greater detail in other sections of the labeling:
- Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]
- Hypertension [see WARNINGS AND PRECAUTIONS]
- Lab test alterations [see WARNINGS AND PRECAUTIONS]
Adverse Reactions in Clinical Trials
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice. In two randomized clinical studies [Studies 1 and 2, See Clinical Studies], a total of 1,775 patients were exposed to Injectafer 15 mg/kg body weight up to a maximum single dose of 750 mg of iron on two occasions separated by at least 7 days up to a cumulative dose of 1500 mg of iron.
Adverse reactions reported by ≥ 1% of treated patients are shown in the following table.
Table 1: Adverse reactions
reported in ≥ 1% of Study Patients in Clinical Trials 1 and 2
|Blood Phosphorus Decrease||2.1||0.1||0.0|
|Injection Site Discoloration||1.4||0.3||0.0|
|Alanine Aminotransferase Increase||1.1||0.2||0.0|
|a Includes oral iron and all formulations of IV iron other than Injectafer|
Other adverse reactions reported by ≥ 0.5% of treated patients include abdominal pain, diarrhea, gamma glutamyl transferase increased, injection site pain/irritation, rash, paraesthesia, sneezing. Transient decreases in laboratory blood phosphorus levels ( < 2 mg/dL) have been observed in 27% (440/1638) patients in clinical trials.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following serious adverse reactions have been most commonly reported from the post-marketing spontaneous reports with Injectafer: urticaria, dyspnea, pruritis, tachycardia, erythema, pyrexia, chest discomfort, chills, angioedema, back pain, arthralgia, and syncope. One case of hypophosphatemic osteomalacia was reported in a subject who received 500 mg of Injectafer every 2 weeks for a total of 16 weeks. Partial recovery followed discontinuation of Injectafer.
Read the Injectafer (ferric carboxymaltose injection) Side Effects Center for a complete guide to possible side effects
Formal drug interaction studies have not been performed with Injectafer .This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/7/2017
Additional Injectafer Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.